1. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
- Author
-
López-Pérez R, García-Sanz R, González D, Balanzategui A, Chillón MC, Alaejos I, Mateos MV, Caballero MD, Corral M, Orfão A, González M, and San Miguel JF
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cell Count, Clone Cells chemistry, Combined Modality Therapy, Cyclophosphamide pharmacology, Dexamethasone administration & dosage, Disease-Free Survival, Granulocyte Colony-Stimulating Factor pharmacology, Hematopoietic Stem Cell Mobilization methods, Humans, Immunophenotyping, Interferons administration & dosage, Life Tables, Middle Aged, Multiple Myeloma blood, Multiple Myeloma drug therapy, Multiple Myeloma mortality, Prospective Studies, Reproducibility of Results, Salvage Therapy, Sensitivity and Specificity, Survival Analysis, Transplantation, Autologous, Treatment Outcome, Blood Component Removal, Bone Marrow Purging methods, Gene Rearrangement, B-Lymphocyte, Heavy Chain, Hematopoietic Stem Cell Transplantation, Multiple Myeloma therapy, Myeloma Proteins genetics, Neoplastic Cells, Circulating chemistry, Plasma Cells chemistry, Polymerase Chain Reaction methods
- Abstract
Contaminating tumour cells in apheresis products have proved to influence the outcome of patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (APBSCT). The gene scanning of clonally rearranged VDJ segments of the heavy chain immunoglobulin gene (VDJH) is a reproducible and easy to perform technique that can be optimised for clinical laboratories. We used it to analyse the aphereses of 27 MM patients undergoing APBSCT with clonally detectable VDJH segments, and 14 of them yielded monoclonal peaks in at least one apheresis product. The presence of positive results was not related to any pre-transplant characteristics, except the age at diagnosis (lower in patients with negative products, P = 0.04). Moreover, a better pre-transplant response trended to associate with a negative result (P = 0.069). Patients with clonally free products were more likely to obtain a better response to transplant (complete remission, 54% vs 28%; >90% reduction in the M-component, 93% vs 43% P = 0.028). In addition, patients transplanted with polyclonal products had longer progression-free survival, (39 vs 19 months, P = 0.037) and overall survival (81% vs 28% at 5 years, P = 0.045) than those transplanted with monoclonal apheresis. In summary, the gene scanning of apheresis products is a useful and clinically relevant technique in MM transplanted patients.
- Published
- 2001
- Full Text
- View/download PDF